FMDB37 | Ashar MN Chad R | Ashar04 | Fermented Milk containing ACE-inhibitory peptides reduces blood pressure in middle aged hypertensive subjects | SKVYPFPGPI | SKVYPFPGPI | 10 | Whey protein | β-Casein | NA | NA | NA | NA | NA | NA | NA | Lactobacillus delbrueckii ssp. bulgaricus | NA | NA | NA | NA | 1.7 mg/ml |
FMDB204 | NA | pan10 | Optimization of sour Milk fermentation for the production of ACE-inhibitory peptides and purification of a novel peptide from Whey protein hydrolysate | RLSFNP | RLSFNP | 6 | Whey protein | Bovine Beta lactoglobulin | 7.5 | 39C | 20h | Ace-inhibitory | In vitro | NA | Spectrophotometric asay using HHL as substrate | Lb. helveticus LB10 | proteinase and peptidase | RPHLC &triple-quadruple mas spectrometer ESI-MS/MS | NA | 732.84Da | 177.39 μm. |
FMDB337 | 16476172 | NA | NA | WLAHK | WLAHK | 5 | goat Whey | Alpha lactoglobulin | NA | NA | NA | Ace-inhibitory | In vitro | NA | NA | Can parapsilosis and Lb paracasei | protease | NA | NA | NA | NA |
FMDB1195 | 25218972 | NA | NA | LAFNPTQLEGQCHV | LAFNPTQLEGQCHV | 14 | Sheep cheese Whey | ovine βlactoglobulin, f(149–162) | NA | 45c | 4h | Ace-inhibitory | In vitro | NA | Spectrophotometric assay using HHL as substrate | Bacillus sp.P7 | protease | nano-ESI-MS | 778.8811 | NA | NA |
FMDB1196 | 25218972 | NA | NA | LAFNPTQLEGQCHV | LAFNPTQLEGQCHV | 14 | Sheep cheese Whey | ovine βlactoglobulin, f(149–162) | NA | 45c | 4h | Antioxidant | In vitro | NA | ABTS radical scavenging assay | Bacillus sp.P7 | protease | nano-ESI-MS | 778.8811 | NA | NA |
FMDB1818 | 15328207 | | Structural Analysis of a New Anti-Hypertensive Peptide (β-Lactosin B) Isolated from a Commercial Whey Product | ALPM “β-lactosin B” | ALPM | 5 | commercial Whey product, WE80BG | β-lactoglobulin | NA | NA | NA | Ace-inhibitory | In vitro | NA | Spectrophometric assay using HHL as substrate | NA | NA | RPHPLC and N terminal sequencing by Edman degradation | NA | NA | 928uM |
FMDB1819 | 15328207 | NA | Structural Analysis of a New Anti-Hypertensive Peptide (β-Lactosin B) Isolated from a Commercial Whey Product | ALPM “β-lactosin B” | ALPM | 5 | commercial Whey product, WE80BG | β-lactoglobulin | NA | NA | NA | Anti-hypertensive | In vivo | NA | NA | NA | NA | RPHPLC and N terminal sequencing by Edman degradation | NA | NA | 928uM |
FMDB1905 | NA | tsai08 | Antihypertensive effect of bioactive peptides produced by protease-facilitated lactic acid fermentation of Milk | YPYY | YPYY | 4 | Fermented Milk Whey product (4.5% (w/v) skimmed Milk powder, 5.5% (w/v) whole Milk powder and 7% (w/v) sucrose ) | Casein | NA | 43c | 5h | Ace-inhibitory | In vitro | NA | RP-HPLC modified spectrophotometric assay using HHL as substrate | Streptococcus thermophilus and Lactobacillus bulgaricus + . Flavourzyme from Aspergillus oryzae | protease | RP-HPLC and protein sequencer 492 Procise | NA | NA | 90.9uM |
FMDB1906 | NA | tsai08 | Antihypertensive effect of bioactive peptides produced by protease-facilitated lactic acid fermentation of Milk | YPYY | YPYY | 4 | Fermented Milk Whey product (4.5% (w/v) skimmed Milk powder, 5.5% (w/v) whole Milk powder and 7% (w/v) sucrose ) | Casein | NA | 43c | 5h | Ace-inhibitory | In vivo | spontaneously Hypertensive Rats | NA | Streptococcus thermophilus and Lactobacillus bulgaricus + . Flavourzyme from Aspergillus oryzae | protease | RP-HPLC and protein sequencer 492 Procise | NA | NA | 90.9uM |
FMDB2041 | NA | ahn09 | ANGIOTENSIN I-CONVERTING ENZYME (ACE) INHIBITORY PEPTIDES FROM WHEY FERMENTED BY LACTOBACILLUS SPECIES | AEKTK | AEKTK | 5 | Reconstituted Whey powder | b-lactoglobulin f73–77 | 6 | 37C | 36h | Ace-inhibitory | In vitro | NA | Spectrophotometric assay using HHL as substate | Lb. brevisKCTC3102 | NA | RP-HPLc and soild phase Edman peptide sequencing | NA | NA | 509.1± 0.000ug/ml |
FMDB2042 | NA | ahn09 | ANGIOTENSIN I-CONVERTING ENZYME (ACE) INHIBITORY PEPTIDES FROM WHEY FERMENTED BY LACTOBACILLUS SPECIES | AQSAP | AQSAP | 5 | Reconstituted Whey powder | b-lactoglobulin f34–38 | 6 | 37C | 36h | Ace-inhibitory | In vitro | NA | Spectrophotometric assay using HHL as substate | Lb. helveticus ATCC 15009 | NA | RP-HPLc and soild phase Edman peptide sequencing | NA | NA | 238.6 ±49.20ug/ml |
FMDB2043 | NA | ahn09 | ANGIOTENSIN I-CONVERTING ENZYME (ACE) INHIBITORY PEPTIDES FROM WHEY FERMENTED BY LACTOBACILLUS SPECIES | IPAVF | IPAVF | 5 | Reconstituted Whey powder | b-lactoglobulin f78–82 | 6 | 37C | 36h | Ace-inhibitory | In vitro | NA | Spectrophotometric assay using HHL as substate | Lb. helveticus ATCC 15009 | NA | RP-HPLc and soild phase Edman peptide sequencing | NA | NA | 5.3 ±0.100ug/ml |
FMDB2044 | NA | ahn09 | ANGIOTENSIN I-CONVERTING ENZYME (ACE) INHIBITORY PEPTIDES FROM WHEY FERMENTED BY LACTOBACILLUS SPECIES | APLRV | APLRV | 5 | Reconstituted Whey powder | b-lactoglobulin f37–41 | 6 | 37C | 36h | Ace-inhibitory | In vitro | NA | Spectrophotometric assay using HHL as substate | Lb. helveticus ATCC 15009 | NA | RP-HPLc and soild phase Edman peptide sequencing | NA | NA | 5.3 ±0.100ug/ml |
FMDB2045 | NA | ahn09 | ANGIOTENSIN I-CONVERTING ENZYME (ACE) INHIBITORY PEPTIDES FROM WHEY FERMENTED BY LACTOBACILLUS SPECIES | AHKAL | AHKAL | 5 | Reconstituted Whey powder | α-LA f106–110 | 6 | 37C | 36h | Ace-inhibitory | In vitro | NA | Spectrophotometric assay using HHL as substate | Lb. helveticus ATCC 15009 | NA | RP-HPLc and soild phase Edman peptide sequencing | NA | NA | 5.3 ±0.100ug/ml |